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Psoriasis and Other Complex Trait Dermatoses:
From Loci to Functional Pathways
Francesca Capon1, A. David Burden2, Richard C. Trembath1 and Jonathan N. Barker1
Driven by advances in molecular genetic technologies
and statistical analysis methodologies, there have
been huge strides taken in dissecting the complex
genetic basis of many inflammatory dermatoses. One
example is psoriasis, for which application of classical
linkage analysis and genome-wide association inves-
tigation has identified genetic loci of major and minor
effect. Although most loci independently have modest
genetic effects, they identify important biological
pathways potentially relevant to disease pathogenesis
and therapeutic intervention. In the case of psoriasis,
these appear to involve the epidermal barrier, NF-kB
mechanisms, and T helper type 17 adaptive immune
responses. The advent of next-generation sequencing
methods will permit a more detailed and complete
map of disease genetic architecture, a key step in
developing personalized medicine strategies in the
clinical management of the complex inflammatory
dermatoses.
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INTRODUCTION
In some way or other all diseases have a genetic basis.
Although this is obvious for Mendelian conditions including
the genodermatoses (see review 1), at least in part the same
holds true for all acquired diseases, extending from cancer,
through metabolic, degenerative, and inflammatory diseases
to infectious diseases. In the latter, the host’s response to the
pathogen, which determines the clinical phenotype and
outcome, is, as exemplified by leprosy, in great part under
genetic control (Vannberg et al., 2011). This provides an
example of how genes and environment may interact to
cause disease.
In contrast to Mendelian diseases where very rare variants
(mutations) have a major effect on disease phenotype, in
common traits the genetic contribution is complex. In a small
number of cases, rare alleles with major effect and in others
low-frequency variants of intermediate effect may be
responsible. However, in the large majority of cases,
common variants of small individual effect are likely to be
involved. Building upon technological advances and on the
wealth of information generated by the HapMap and the
1000 Genomes project (Altshuler et al., 2010; The 1000
Genomes Project Consortium, 2010), huge strides have been
made in determining the genetic architecture of common,
complex diseases.
Within dermatology are a group of disorders that are
commonly grouped together as the ‘‘inflammatory derma-
toses.’’ Included under this umbrella term are diseases very
frequent within the general population that are the cause
of poor life quality and that, despite several therapeutic
advances, retain significant unmet clinical need. To date,
progress in unraveling fundamental biological pathways of
disease has been sporadic. For these diseases, given their
documented heritability, current and future genetic
approaches hold much promise. Application of such methods
has been outstandingly successful when applied to some of
these inflammatory dermatoses, of which two excellent
examples are AD (atopic dermatitis; OMIM (Online Mende-
lian Inheritance in Man) #603165) and psoriasis (OMIM
#177900). Intriguingly, different approaches were used in
each. For AD, a candidate gene approach based on the
discovery of genetic variants in ichthyosis vulgaris, a
frequently associated disease, led to the key observation
that alterations in filaggrin, and thus the epidermal barrier,
have a key role in pathogenesis (Palmer et al., 2006). Testing
the hypothesis that common variants may have a role in
susceptibility to disease, several genome-wide association
studies (GWASs) have been conducted on psoriasis.
These have confirmed the primary role of the major histo-
compatibility complex (MHC) in disease susceptibility,
while identifying multiple genes of smaller effect, which
nevertheless provide a framework for understanding patho-
genesis and explaining the efficacy of several receptor-
targeted therapies (Ellinghaus et al., 2010; Huffmeier et al.,
2010; Strange et al., 2010; Stuart et al., 2010; Sun et al.,
2010). The GWAS approach has been applied to many
other inflammatory dermatoses including vitiligo (OMIM
#193200), alopecia areata (OMIM #104000), and AD, with
varying degrees of success (Jin et al., 2010a, b; Petukhova
et al., 2010).
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This article provides a perspective on the application of
genetics to the complex trait psoriasis, what information it has
provided, the clinical and therapeutic implications, and what
it potentially means for personalized medicine. Psoriasis is
used as a model for the article, but clearly the principles it
demonstrates are applicable to other dermatoses such as AD
and acne vulgaris (OMIM #604324).
PSORIASIS AS A COMPLEX TRAIT DERMATOSIS
Background
For the past 200 years, psoriasis has been defined primarily
by its clinical appearance. The spectrum of what are now
considered to be psoriatic diseases demonstrates marked
heterogeneity in clinical morphology (e.g., plaques or
pustules), distribution, and disease severity, such that it
remains unclear to what extent these represent different
manifestations of the same inflammatory process or distinct
disease entities. Even within the apparently more homo-
genous subgroup of psoriasis vulgaris (chronic plaque
psoriasis), heterogeneity has been demonstrated between
disease of early-onset (before 40 years of age) and later-onset
disease (Henseler and Christophers, 1985), and further
subdivisions seem probable (Griffiths et al., 2007). The
phenotype of psoriasis vulgaris has long been recognized
to pass from one generation to the next but, with rare
exceptions, without a Mendelian pattern of inheritance. The
heritability of this form of psoriasis has been confirmed in
twin studies, from which it can be estimated thatB80% of its
phenotypic variance can be attributed to genetics (Brandrup
et al., 1982). However, there are few data concerning the
extent to which the phenotype, including, for instance, the
presence of psoriatic arthritis or disease severity, breed true in
pedigrees. Although precipitants such as infection are well
established, the role of other environmental factors in
determining disease susceptibility is less clear.
Linkage studies and the identification of PSORS1
The familial recurrence of psoriasis being well established,
the disease has long been considered a complex genetic trait,
resulting from gene–gene and gene–environment interactions
(Nestle et al., 2009). As methods for linkage analysis of
multifactorial conditions were developed in the early 1990s,
several genome-wide scans were undertaken, with a view to
pursuing the search for psoriasis susceptibility genes by
means of positional cloning. These studies provided very
robust evidence for the presence of a disease susceptibility
locus (named PSORS1 (psoriasis susceptibility 1)) lying within
the MHC, on chromosome 6p21.3 (Capon et al., 2002). It is
noteworthy that the pathogenic involvement of the MHC was
consistent with the results of previous serological studies,
which had repeatedly identified an association between
psoriasis and the HLA-Cw6 allele (Tiilikainen et al., 1980;
Mallon et al., 1999).
Outside of the MHC, genome-wide linkage scans gener-
ated conflicting results (Capon et al., 2004b) and even the
joint analysis of multiple family resources failed to validate
any of the susceptibility regions that had emerged from these
studies (The International Psoriasis Genetics Consortium,
2003). This phenomenon was by no means unique to
psoriasis, as the poor performance of genome-wide linkage
scans was plaguing the analysis of most complex traits. In
fact, it eventually became apparent that linkage studies
lacked the statistical power to detect common susceptibility
loci with small phenotypic effects (Risch, 2000).
The search for the PSORS1 susceptibility gene
As linkage studies demonstrated that PSORS1 was the major
genetic determinant for psoriasis susceptibility (Nair et al.,
1997; Trembath et al., 1997), several attempts were made to
define a minimal disease interval and to identify the gene
underlying the linkage signal. A linkage disequilibrium–based
fine-mapping approach was undertaken by different groups,
who analyzed dense microsatellite maps across the PSORS1
locus, searching for markers that showed association, as well
as linkage, with the disease (Nair et al., 2000; Veal et al.,
2002). These efforts led to the identification of a 250-kb
critical interval, which spanned part of the MHC class I
region and included nine genes (Capon et al., 2002). Among
these, HLA-C (human leukocyte antigen C), CCHCR1 (coiled-
coil a-helical rod protein 1), and CDSN (corneodesmosin)
rapidly emerged as attractive candidate genes, based on their
function and on the presence of disease-associated alleles
within their coding sequence.
HLA-C has a fundamental role in immune responses as it
encodes a class I MHC molecule involved in the process of
antigen presentation to CD8þ T lymphocytes (Falk et al.,
1993). Highly significant association between psoriasis and
the HLA-Cw6 allele has been reported in a wide range of
populations, leading some researchers to propose that HLA-
Cw6 might be the causal disease susceptibility allele at the
PSORS1 locus (Capon et al., 2002).
CCHCR1 encodes a protein of unknown function, which is
overexpressed in the skin lesions of psoriatic patients
(Asumalahti et al., 2000). Genetic studies identified an
intragenic haplotype, which consisted of four nonsynon-
ymous substitutions and was associated with psoriasis
susceptibility across multiple populations (Asumalahti et al.,
2002). Transcriptome profiling of transgenic mice carrying
the risk CCHCR1 haplotype revealed changes in the
expression of genes involved in keratinocyte terminal
differentiation, suggesting that variation at this locus has
functional consequences that are relevant to the pathogenesis
of psoriasis (Elomaa et al., 2004).
CDSN codes for a keratinocyte structural protein that is
involved in the process of skin desquamation, which is
typically altered in psoriasis (Guerrin et al., 1998). Associa-
tions between CDSN coding polymorphisms and psoriasis
susceptibility were reported in several populations of
European and Asian descent (Hui et al., 2002; Capon et al.,
2003). Functional studies demonstrated that one disease-
associated variant affected the stability of CDSN mRNA
(Capon et al., 2004a) and possibly accounted for the gene
overexpression in patient skin lesions (Allen et al., 2001).
Despite these efforts at characterizing and validating
disease association, the interpretation of genetic studies was
constantly confounded by the conservation of linkage
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disequilibrium across PSORS1. With highly significant
associations observed at all three gene loci, the identification
of the causal disease susceptibility allele proved to be an
extremely challenging task (Capon et al., 2002). In an attempt
to overcome this difficulty, the entire PSORS1 region was
sequenced in individuals bearing different HLA-C alleles,
with a view to identifying single-nucleotide polymorphisms
(SNPs) that were unique to the PSORS1 risk haplotype. The
results of these experiments suggested that HLA-C was the
most likely PSORS1 candidate gene (Nair et al., 2006).
Genome-wide association studies
Although theoretical calculations have long established that
association studies are ideally suited to the identification loci
of small genetic effect (Risch, 2000), the implementation of
GWAS has only become achievable in the past 5 years,
thanks to our improved understanding of human genetic
variation and to technological advances in high-throughput
genotyping (The International HapMap Consortium, 2005;
Frazer et al., 2007). Since the Wellcome Trust Case Control
Consortium carried out a landmark study of seven common
conditions (The Wellcome Trust Case-Control Consortium,
2007), GWASs have become the instrument of choice in the
analysis of complex traits. Whenever these studies have been
applied to the analysis of adequately powered and carefully
phenotyped data sets, they have been successful, leading to
the identification of hundreds of disease susceptibility
regions. The field of psoriasis genetics has embraced these
advances, and nine GWASs have been carried out in the past
few years (Cargill et al., 2007; Capon et al., 2008; Nair et al.,
2009; Zhang et al., 2009; Ellinghaus et al., 2010; Huffmeier
et al., 2010; Strange et al., 2010; Stuart et al., 2010; Sun et al.,
2010). These studies have included increasingly large sample
sizes, reflecting a trend documented for most common
and complex traits. At the same time, the design of
these experiments has remained fundamentally unchanged,
with the typical GWAS consisting of the analysis of
500,000–1,000,000 SNPs in a discovery data set, followed
by the validation of the most significant findings in an
independently ascertained resource (Figure 1). This approach
has proved to be extremely robust and has allowed the
identification of 22 novel psoriasis susceptibility regions.
Although these disease-associated intervals tend to encom-
pass several transcripts, most regions include at least one
immune-related gene. Remarkably, the proteins encoded by
these positional candidate genes appear to contribute to a
small number of signaling pathways (Table 1 and Figure 2).
Thus, the elevated statistical significance of the HLA-C
association highlights the fundamental importance of antigen
presentation in psoriasis. This notion is reinforced by the
identification of disease susceptibility alleles within the
ERAP1 (endoplasmic reticulum amino-peptidase 1) gene,
which encodes a peptidase contributing to the generation of
class I MHC ligands (York et al., 2002). It is noteworthy that a
genetic interaction between HLA-C and ERAP1 has been
documented, whereby ERAP1 variants confer disease sus-
ceptibility only in individuals carrying the HLA-C risk allele
(Strange et al., 2010). Given the small number of known
interactions between complex disease loci, this is a remark-
able observation, which emphasizes the significance of HLA-
Cw6-restricted responses in psoriasis. At the same time, the
associations at the IL12B (IL-12B), IL23A (IL-23A), IL23R
(IL-23 receptor), and TRAF3IP2 (TRAF3-interacting protein 2)
loci underscore the pathogenic involvement of the IL-23/IL-
17 axis. Similarly, the presence of susceptibility alleles within
the IFIH1 (IFN induced with helicase C domain 1), RNF114
(ring finger protein 114), IL28RA (IL-28 receptor a), and TYK2
(tyrosine kinase 2) gene regions highlight a hitherto unsus-
pected role for the disruption of innate antiviral responses.
Finally, the pathogenic impact of NF-kB signaling dysregula-
tion is illustrated by the associations observed at the REL
(v-rel viral oncogene homolog), NFKBIA (NF-kB inhibitor a),
TNFAIP3 (tumor necrosis factor a induced protein 3), and
TNIP1 (TNFAIP3-interacting protein 1) genes. It is noteworthy
that key genes from all the above pathways have also been
implicated in other immune-mediated conditions (Table 2),
suggesting a genetic basis for the well-documented occur-
rence of systemic comorbidities in psoriasis (Griffiths and
Barker, 2007). Taken together, these results demonstrate the
impact of GWAS on our understanding of disease processes.
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Figure 1. An example of a Manhattan plot summarizing the association results generated by a genome-wide association scan (GWAS). Single-nucleotide
polymorphisms (SNPs) are plotted according to their chromosomal location, and each dot represents the P-value (plotted as log10 P) associated with a single
marker. Green dots refer to susceptibility regions that were known at the onset of the study, with the PSORS1 signal (which generated a Po10200, but is cut
here at P¼ 1010) on chromosome 6 dominating the genetic landscape. Red dots highlight novel susceptibility loci (reproduced from Strange et al., 2010).
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Although the individual genetic determinants identified
by these studies confer modest increases in disease risk
(with odds ratios typically ranging between 1.1 and 1.5),
they collectively identify a small number of key pathogenic
pathways that could be usefully targeted with novel thera-
peutic agents.
The post-GWAS era
Despite the remarkable success of GWASs, a significant
proportion of psoriasis heritability remains unaccounted for.
This phenomenon, which has been documented across most
complex diseases (Maher, 2008), may be due to the lack of
statistical power of the GWASs that have been carried out so
Table 1. Genes associated with psoriasis susceptibility1
Gene2 (location) Protein function Pathway References
IL23R (1p31) IL-23 receptor subunit IL-23 signaling Cargill et al. (2007); Capon et al. (2008);
Nair et al. (2009); Ellinghaus et al. (2010);
Strange et al. (2010)
IL28RA (1p36) IL-29 receptor subunit IFN signaling Strange et al. (2010)
LCE3B/3C/3D (1q21) Keratinocyte structural protein Skin barrier function de Cid et al. (2009); Zhang et al. (2009);
Ellinghaus et al. (2010)
REL (2p16) NF-kB subunit NF-kB signaling Strange et al. (2010)
IFIH1/MDA5 (2q24) Innate antiviral receptor IFN signaling Strange et al. (2010)
ERAP1 (5q15) Amino peptidase processing
MHC class I ligands
Antigen presentation Strange et al. (2010); Sun et al. (2010)
IL4, IL13 (5q31) Th2 cytokines IL-4/IL-13 signaling Nair et al. (2009)
IL12B (5q33) Subunit shared by the IL-12 and
IL-23 cytokines
IL-23 signaling Cargill et al. (2007); Nair et al. (2009);
Zhang et al. (2009); Ellinghaus et al. (2010);
Huffmeier et al. (2010)3
TNIP1 (5q33) Inhibitor of TNF-induced NF-kB
activation
NF-kB signaling Nair et al. (2009); Strange et al. (2010);
Sun et al. (2010)
PTTG1 (5q33) Anaphase-promoting complex substrate Cell cycle control/DNA repair Sun et al. (2010)
HLA-C (6p21) MHC class I antigen Antigen presentation Capon et al. (2008); Nair et al. (2009);
Zhang et al. (2009);
Ellinghaus et al. (2010); Strange et al. (2010)
TRAF3IP2 (6q21) Adaptor mediating IL-17-induced
NF-kB activation
IL-17/NF-kB signaling Ellinghaus et al. (2010); Strange et al. (2010);
Huffmeier et al. (2010)3
TNFAIP3 (6q23) Inhibitor of TNF-induced NF-kB activation NF-kB signaling Nair et al. (2009); Strange et al. (2010)
CSMD1 (8p23) Tumor-suppressor gene Unknown Sun et al. (2010)
IL23A (12q13) IL-23 subunit IL-23 signaling Nair et al. (2009); Strange et al. (2010)
GJB2 (13q11) Gap junction protein Electrolyte transport Sun et al. (2010)
NFKBIA (14q13) Inhibitor of NF-kB activation NF-kB signaling Strange et al. (2010); Stuart et al. (2010)
FBXL19 (16p11) Putative inhibitor of NF-kB activation NF-kB signaling Stuart et al. (2010)
NOS2 (17q11) Induced nitric oxide synthase Innate antibacterial response Stuart et al. (2010)
SERPINB8 (18q21) Serine protease inhibitor Unknown Sun et al. (2010)
TYK2 (19p13) Tyrosine kinase associated with
cytokine receptors
IL-23 and IFN signaling Strange et al. (2010)
ZNF816A (19q13) Zinc-finger protein Unknown Sun et al. (2010)
ZNF313/RNF114
(20q13)
E3 ubiquitin ligase IFN signaling Capon et al. (2008); Nair et al. (2009);
Strange et al. (2010); Stuart et al. (2010)
Abbreviations: CSMD1, CUB and Sushi multiple domains 1; ERAP1, endoplasmic reticulum amino-peptidase 1; FBXL19, F-box and leucine-rich repeat
protein 19; GJB2, gap junction protein, b2, 26 kDa; HLA-C, human leukocyte antigen C; IFIH1, IFN induced with helicase C domain 1; IL12B, IL-12B;
IL28RA, IL-28 receptor a; LCE3B, late cornified envelope 3B; MDA5, melanoma differentiation-associated gene 5; MHC, major histocompatibility complex;
NFKBIA, NF-kB inhibitor a; PTTG1, pituitary tumor-transforming 1; REL, v-rel viral oncogene homolog; RNF114; ring finger protein 114; SERPINB8, serpin
peptidase inhibitor, clade B (ovalbumin), member 8; TNFAIP3, tumor necrosis factor, a-induced protein 3; TNIP1, TNFAIP3-interacting protein 1; TRAF3IP2,
TRAF3-interacting protein 2; TYK2, tyrosine kinase 2; ZNF816A, zinc finger protein 816.
1All the loci included in the table showed genome-wide significant association (Po5108) with psoriasis, in at least one genome-wide association scan
(GWAS).
2Gene of interest found in the disease-associated susceptibility interval.
3Psoriatic arthritis GWAS.
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far. In this context, the ongoing meta-analysis of three large
studies (Ellinghaus et al., 2010; Strange et al., 2010; Stuart
et al., 2010) is expected to uncover novel genetic deter-
minants for the disease. At the same time, it is generally
recognized that the current genotyping platforms present a
number of limitations, which will affect the outcome of
GWASs, regardless of the size of the examined sample. First
of all, genotyping chips only include a fraction of the SNPs
that have been annotated for the human genome. Thus, the
effect size of the causal susceptibility SNPs that are not
represented in current platforms can only be estimated on the
basis of the data that are available for their genotyped
proxies. To address this issue, the Immunochip Consortium
has recently developed a custom genotyping platform, which
includesB200,000 SNPs spanning4150 regions associated
with immune-mediated conditions. The use of the Immuno-
chip for the analysis of large case–control data sets is
expected to identify the causal susceptibility alleles for most
of the above loci, thus facilitating the interpretation of GWAS
findings for conditions such as psoriasis, rheumatoid arthritis,
or Crohn’s disease (Cortes and Brown, 2011).
Another limitation of GWAS is the underrepresentation of
rare variants (generally defined as SNPs occurring at a
frequency of o5%) on genotyping chips. This is of some
importance, as studies carried out in other complex diseases
have demonstrated that rare susceptibility alleles can have a
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Figure 2. Genetic studies suggest an integrated model for the pathogenesis
of psoriasis. Alterations in skin barrier and immune genes determine
abnormal responses to external agents (e.g., viruses detected by IFIH1
(IFN induced with helicase C domain 1)), resulting in chronic skin
inflammation. CCHCR1, coiled-coil a-helical rod protein 1; CDSN,
corneodesmosin; ERAP1, endoplasmic reticulum amino-peptidase 1;
HLA-C, human leukocyte antigen C; IL12B, IL-12B; IL28RA, IL-28 receptor a;
LCE3C, late cornified envelope 3C; NFKBIA, NF-kB inhibitor a; PSORS1,
psoriasis susceptibility 1; REL, v-rel viral oncogene homolog; RNF114,
ring finger protein 114; TNFAIP3, tumor necrosis factor, a-induced protein 3;
TNIP1, TNFAIP3-interacting protein 1; TRAF3IP2, TRAF3-interacting protein 2;
TYK2, tyrosine kinase 2; ZAP70, zeta-chain (TCR) associated protein kinase
70 kDa; ZNF816A, zinc finger protein 816.
Table 2. Pleiotropic disease susceptibility genes
associated with psoriasis
Gene Other associated diseases References
IL23R Crohn’s disease
Ankylosing spondylitis
Duerr et al. (2006);
Burton et al. (2007)
REL Rheumatoid arthritis
Celiac disease
Crohn’s disease
Gregersen et al.
(2009);
Trynka et al. (2009);
Franke et al. (2010)
IFIH1 Type 1 diabetes Smyth et al. (2006);
Nejentsev et al.
(2009)
ERAP1 Ankylosing spondylitis Burton et al. (2007)
CDKAL1 Crohn’s disease
Type 2 diabetes
Zeggini et al. (2007);
Barrett et al. (2008);
Quaranta et al. (2009)
IL12B Crohn’s disease
Ulcerative colitis
Parkes et al. (2007);
Fisher et al. (2008)
PTTG1 Systemic lupus erythematosus Han et al. (2009)
TNIP1 Systemic lupus erythematosus Gateva et al. (2009)
TNFAIP3 Rheumatoid arthritis
Systemic lupus erythematosus
Celiac disease
Plenge et al. (2007);
Thomson et al. (2007);
Graham et al. (2008);
Musone et al. (2008);
Trynka et al. (2009)
TYK2 Type 1 diabetes
Multiple sclerosis
Systemic lupus erythematosus
Crohn’s disease
Sigurdsson et al.
(2005);
Australia and New
Zealand
Multiple Sclerosis
Genetics Consortium
(ANZgene) (2009);
Franke et al. (2010);
Wallace et al. (2010)
Abbreviations: CDKAL1, CDK5 regulatory subunit associated protein 1-
like 1; ERAP1, endoplasmic reticulum amino-peptidase 1; IFIH1, IFN
induced with helicase C domain 1; IL12B, IL-12B; IL23R, IL-23 receptor;
PTTG1, pituitary tumor-transforming 1; REL, v-rel viral oncogene
homolog; TNFAIP3, tumor necrosis factor, a-induced protein 3; TNIP1,
TNFAIP3-interacting protein 1; TYK2, tyrosine kinase 2.
www.jidonline.org 919
F Capon et al.
Genetic Basis of Common Dermatoses
role in the pathogenesis of common conditions (Nejentsev
et al., 2009). The high-throughput mutational analyses that
are required for the identification of these rare alleles are now
becoming a realistic prospect, thanks to the development of
next-generation sequencing technologies. These techniques
generate vast amounts of sequence information, which
require the setup of complex bioinformatic pipelines
and carefully designed follow-up protocols. Despite this
difficulty, next-generation sequencing has already had a
significant impact on the discovery of rare Mendelian
mutations (Teer and Mullikin, 2010) and is showing great
promise as a tool for the identification of genes underlying
severe forms of skin inflammation (Onoufriadis et al., 2011;
Marrakchi et al., 2011). Thus, the next few years are expected
to witness significant progress in the characterization of rare
sequence variants and in the understanding of their patho-
genic role.
Finally, GWASs based on the analysis of bi-allelic SNPs
have very limited power for the detection of complex copy
number variants. In fact, the only multi-allelic copy number
variant to be associated with psoriasis is a b-defensin cluster
polymorphism (Hollox et al., 2008), which was identified in a
candidate gene study. As copy number variants are expected
to have significant phenotypic effects (Estivill and Armengol,
2007), ad-hoc genotyping platforms will have to be devel-
oped, in order to fully explore their pathogenic potential.
OTHER DERMATOSES AND INFLAMMATORY SKIN
DISORDERS
As mentioned in the Introduction, there are multiple other
complex trait dermatoses, and one would anticipate that the
application of the techniques detailed above would likely
provide great insights into disease pathophysiology. Two
examples of recent progress are generalized vitiligo (Jin et al.,
2010a, b) and alopecia areata (Petukhova et al., 2010). In
both examples, GWASs were performed and, interestingly, as
in the case of psoriasis, revealed evidence for the involve-
ment of genes involved in target cell/tissue biology as well
as genes involved in the immune response. In the case of
alopecia areata, a GWAS revealed strongest association for
SNPs within the MHC (max P-value¼ 1.381035), whereas
genome-wide significance was achieved for genes involved
in both innate (e.g., ULBP6 (UL16 binding protein)) and
adaptive (e.g., CTLA4 (cytotoxic T-lymphocyte–associated
protein 4)) immunity. Direct evidence for involvement of
genes within the hair follicle was also observed (Petukhova
et al., 2010). These results underpin the concept of a genetic
basis for organ-specific autoimmune disease.
The other important complex trait dermatosis, to which
genetics have provided crucial insights into relevant func-
tional pathways, is AD. Unlike psoriasis, GWASs have to date
been somewhat disappointing. However, the critical finding
in AD of the association of loss-of-function mutations in
filaggrin (Palmer et al., 2006) was discovered through a
candidate gene approach following the clinical observation
of the coexistence of AD with ichthyosis vulgaris, an
autosomal semidominant disease (Brown and McLean,
2009). When this observation is taken together with
candidate loci and genes observed in at least two genome-
wide linkage studies, yet again the concept of a genetic
etiology involving target organ (epidermis) and immunologi-
cal genes surfaces.
CONCLUSIONS
The rate of discovery of potential psoriasis genes in the past
5 years has been astonishing. The national and international
collaborations necessary to assemble thousands of accurately
phenotyped individuals and for large-scale genotyping have
fundamentally changed the research environment. However,
identifying associated SNPs is only the first step in the process
of gaining a better understanding of the nature of these
diseases and of translation of this information into clinical
applications. Identified loci require fine mapping, and the
functional effects of risk variants on, for instance, gene
transcription, RNA splicing, or protein function need to be
determined.
The impact on the management of psoriasis of translating
genetic information into the clinic is potentially enormous.
Currently, too small a proportion of the heritability of the
disease is accounted for by known loci for genotyping to
contribute to the diagnosis of psoriasis, but it can be
anticipated that rare genetic mutations of major effect will
be identified in severe psoriasis phenotypes that may be
useful in subclassifying psoriatic diseases. As the genetic
architecture of psoriasis is more fully understood, investiga-
tion of gene–environment interactions may suggest interven-
tions that prevent or modify the natural history of psoriasis.
The most immediate consequence of a greater under-
standing of the genetic basis of psoriasis may be in the design
of new drugs, and the selection and monitoring of individual
treatments. Susceptibility loci may prove to be useful
therapeutic targets. In this respect, the high efficacy of
monoclonal antibodies targeting the IL-23/IL-17 axis in
psoriasis is encouraging, given the only modest odds ratios
(1.5) of risk SNPs at IL23R. The genetic heterogeneity of
psoriasis that is already known is currently being explored as
a means of informing selection of currently available
treatments by carrying out pharmacogenetic studies along-
side large psoriasis treatment registers. As more selective
targeted treatments emerge, the likelihood of a differential
responsiveness to treatment between patients depending on
their genotype will increase and identification of genetic
variants that influence the response to drug will be used in
drug selection and dosing for the individual patient.
It is only a matter of time before genetic advances
contribute to the clinical management of many dermatoses
through the development of diagnostic and prognostic
markers and identification of biological pathways relevant
to therapeutic intervention.
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